AI Article Synopsis
- Genetic screening for BRCA mutations can help identify effective treatments for breast, ovarian, and pancreatic cancers, with a focus on the role of olaparib, a PARP inhibitor, in targeting tumors with these mutations.
- A bibliometric analysis of 196 research publications from 2009 to 2022 revealed current trends and global cooperation in the use of olaparib for pancreatic cancer treatment, highlighting notable contributors and key research areas.
- Results show that leading countries like China and the USA are at the forefront of olaparib research, suggesting the need for combination therapies and the emergence of new PARP inhibitors in future treatment strategies.
Article Abstract
Background: Genetic screening for breast cancer gene 1 ()/ mutations can inform breast/ovarian/pancreatic cancer patients of suitable therapeutic interventions. Four to seven percent of pancreatic cancer patients have germline mutations. genes aid in DNA repair, especially homologous recombination, which impacts genomic stability and cancer cell growth. regulates the cell cycle, ubiquitination, and chromatin remodeling, whereas stimulates the immune response. They predict the efficacy of platinum chemotherapy or polymerase (PARP) inhibitors such as olaparib.
Aim: To determine the trends and future directions in the use of olaparib for pancreatic cancer treatment.
Methods: To evaluate the trends in how olaparib works in pancreatic cancer, we performed a bibliometric analysis. One hundred and ninety-six related publications were accessed from the Web of Science Core Collection and were published between 2009 and 2022. The analytic parameters included publications, related citations, productive countries and institutes, influential authors, and keyword development.
Results: This study visualizes and discusses the current research, including the present global trends and future directions in olaparib and pancreatic cancer. Overall, this study sheds light on optimizing the use of olaparib in pancreatic cancer treatment, offering valuable guidance for researchers in this field.
Conclusion: Our findings identified trends in olaparib and pancreatic cancer, with China and the USA leading and with global cooperation tightening. O'Reilly EM's team and Memorial Sloan-Kettering had the highest output. The was the most cited journal. More PARP inhibitors are emerging, and combination therapy is suggested for future therapeutic trends.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551633 | PMC |
| http://dx.doi.org/10.4251/wjgo.v16.i11.4489 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tumor-associated lymphatic vessel density is a postoperative prognostic biomarker of hepatobiliary cancers: a systematic review and meta-analysis.
Front Immunol
January 2025
Department of Hepatobiliary Surgery, The Second Affiliated Hospital, Kunming Medical University, Kunming, China.
Purpose: This study aimed to investigate whether tumor-associated lymphatic vessel density (LVD) could predict the survival of patients with hepato-biliary-pancreatic (HBP) cancers after radical resection.
Methods: A systematic search was conducted using PubMed, Embase, and Cochrane Library from the inception to July 31, 2024 for literature that reported the role of LVD in overall survival (OS) and recurrence-free survival (RFS) of patients with HBP cancers after radical resection.
Results: Ten studies with 761 patients were included for the meta-analysis.
Survival benefits of adjuvant chemotherapy after conversion surgery in patients with advanced pancreatic cancer.
Front Oncol
January 2025
Research Institute, Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, Republic of Korea.
Background: Oncologic outcomes of conversion surgery for advanced pancreatic cancer (PC) have scarcely been reported. Therefore, this study aimed to investigate the outcomes of conversion surgery with preoperative treatment of FOLFIRINOX or gemcitabine with nab-paclitaxel (GnP) for patients with advanced PC including locally advanced or metastatic PC.
Methods: Using the National Health Insurance database between 2005 and 2020, we identified patients who underwent conversion surgery after chemotherapy with FOLFIRINOX or GnP for advanced PC.
Advances and current concepts on Eph receptors and ephrins in upper digestive tract cancers.
Front Oncol
January 2025
Department of Pathology, Faculty of Medical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.
Erythropoietin-producing hepatocellular (Eph) receptors comprise the largest group of surface receptors and are responsible for cellular signals. Eph/ephrin signaling has been identified to play a role in key cancer development and progression processes, especially in the upper gastrointestinal tract. The Eph/ephrin system has been described as a tumor suppressor in duodenal cancer, while in esophageal, gastric, hepatic, and pancreatic cancer, the system has been related to tumor progression.
View Article and Find Full Text PDFImpact of preoperative blood glucose levels on prognosis and postoperative complications in patients with pancreatic cancer.
Oncol Lett
March 2025
Department of Hepatobiliary Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China.
The relationship between diabetes and pancreatic cancer is well documented; however, the effect of preoperative blood glucose levels on prognosis and postoperative complications is currently unclear. The present study aimed to investigate the effect of preoperative blood glucose levels on overall survival (OS) and postoperative complications in patients with pancreatic cancer. This retrospective study included 225 patients with pancreatic cancer treated at The Fourth Hospital of Hebei Medical University from January 2015 to December 2020.
View Article and Find Full Text PDFIdentification and analysis of pancreatic intraepithelial neoplasia: opportunities and challenges.
Front Endocrinol (Lausanne)
January 2025
School of Medicine, The South China University of Technology, Guangzhou, Guangdong, China.
Pancreatic intraepithelial neoplasia (PanIN) is the most common precursor lesion of pancreatic ductal adenocarcinoma (PDAC), which has poor prognosis with a short median overall survival of 6-12 months and a low 5-year survival rate of approximately 3%. It is crucial to remove PanIN lesions to prevent the development of invasive PDAC, as PDAC spreads rapidly outside the pancreas. This review aims to provide the latest knowledge on PanIN risk, pathology, cellular origin, genetic susceptibility, and diagnosis, while identifying research gaps that require further investigation in this understudied area of precancerous lesions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!